Cardiovascular risk factor appraisal art or science? Prof. Philip MacCarthy BSc MBChB (Hons) PhD FRCP Consultant Cardiologist Bupa Cromwell Hospital Clinics: Wednesday & Friday PM/Evening
What are we trying to achieve?
CVD Mortality in England (all <75 yrs) BHF Heart Stats (2012) http://www.bhf.org.uk/publications/view-publication.aspx?ps=1002097
Causes of Death (England, <75 yrs) (Source: Living Well for Longer [ONS data], 2013) Source: www.statistics.gov.uk/ statbase/product.asp?vlnk=6725
CVD.. 200k deaths pa (1:3 of all) 4.9m adults have CVD (11.7% of population) 1.4m hospital admissions in 2010/11 65% were patients under 75 yrs >50% were emergencies CVD costs NHS & UK economy 30bn pa. Prevalence increases with deprivation - Inequalities Services for the prevention of CV Disease NICE Commissioning Guide 45. March 2012
UK causes of Years of Life Lost (both sexes, all ages) 1990-2010 Global Burden of Disease Study. Lancet 2013;381:997-1020 259 diseases and injuries & 67 risk factors
History
The Framingham Heart Study Data collection started in 1948 Bi-annual follow up First CVD risk equation: Truett et al. 1967 > 20 groups of regression equations between 1967 and 2008 Modified Anderson et al 1991 used in UK
Framingham - Anderson Data collected 1968-75 5573 men and women followed up for 12 years Six regression equations published in 1991
Risk factors used to calculate the Anderson Framingham risk score -age and sex -diastolic and systolic BP -total:hdl cholesterol ratio -diabetes (Y/N) -cigarette smoking (Y/N) -LVH (Y/N) Absolute CVD Risk over 10 years
Different versions and coloured charts New Zealand cardiovascular risk prediction charts
Limitations of Framingham BP treatment Family History Deprivation Ethnicity Generalisability Statistical validity Face validity Improvements were needed
A new era of CV risk prediction
SCORE Systematic Coronary Risk Evaluation 2003 205,178 men and women from 12 European cohort studies
SCORE better than Framingham? BP treatment Family History Deprivation Ethnicity Generalisability? Statistical validity Face validity SCORE No No No No Yes No
ASSIGN - ASSessing cardiovascular risk, using SIGN guidelines Scottish Heart and Health Extended Cohort (SHHEC) 6540 men, 6757 women Classic risk factors plus Deprivation Family history Shifts treatment towards the socially deprived compared to Framingham
ASSIGN better than Framingham? SCORE ASSIGN BP treatment No No Family History No Yes Deprivation No Yes Ethnicity No No Generalisability?? Statistical validity Yes Yes Face validity No No
The evolution of QRISK
QRISK1 and QRISK2 Electronic patient record Cohort analysis based on large validated GP database (QResearch) Contains individual patient level data 15 year study period 1993 to 2008 First diagnosis of CVD (including CVD death) QRISK1 Deprivation Family History BMI On BP treatment NO Ethnicity
QRISK 1 QRISK algorithm derived from Derivation cohort 1.28 million patients Validated in the Validation cohort 0.61 million patients QRISK out-performed Framingham and ASSSIGN
QRISK1 - better than Framingham? SCORE ASSIGN QRISK1 BP treatment No No Yes Family History No Yes Yes Deprivation No Yes Yes Ethnicity No No No Generalisability?? Yes Statistical validity Yes Yes Yes Face validity No No Yes
QRISK2 Included ONS deaths linkage Included additional variables 2.3 million people (>16 million person yrs) Self-assigned ethnicity
Age-standardised incidence of CVD by deprivation 12 10 8 6 4 2 Q1 (affluent) Q2 Q3 Q4 Q5 (deprived) 0 females males
Age-standardised incidence of CVD by Ethnicity per 1000 pyrs 25 20 15 10 % White Indian Pakistani Bangladeshi Other Asian Black Caribbean 5 Black African Chinese 0 Females Males Other
Framingham over-predicts QRISK underpredicts Collins and Altman, BMJ 2009;339:2584
QRISK2 better than Framingham? SCORE ASSIGN QRISK1 QRISK2 BP treatment No No Yes Yes Family History No Yes Yes Yes Deprivation No Yes Yes Yes Ethnicity No No No Yes Reproducibility Yes Yes Yes Yes Generalisability?? Yes Yes Statistical validity Yes Yes Yes Yes Face validity No No Yes Yes
How to apply QRisk2 in practice
How to apply QRisk2 in practice
Future developments of QRISK2 A living evidence base
JBS3
http://www.jbs3risk.com Heart 2014;100:ii1-ii67
NICE guidance for statin use
Case study 1 Young female with significant risk factors Effect of intensive risk factor modification 35-year-old female smoker Systolic BP of 160mmHg TC of 7.0mmol/L, HDL of 1.4mmol/L (non-hdl of 5.6mmol/L) Family history of premature CVD
Estimated average survival without a CV event
Estimated average survival without a CV event
Effect of intensive risk factor modification
Effect of intensive risk factor modification
Shortfalls of CV risk scores Not tailored to individual patients Differing views on lifestyle/medications Not completely accurate Is 10yr risk the correct metric? Should be used in the context of clinical common sense!
Further refinement of CV risk Functional testing eg. Exercise ECG/echo Cardiac CT Ca++ scoring/ct angiography PLAC test Genetic testing Other parameters hs-crp, fibrinogen, LP(a)
Lipoprotein-associated phospholipase A2 PLAC test
Predictive value of Lp-PLA2 activity
Cardiac CT Calcium scoring Detrano et al, NEJM 2008;358:1336
Case Study 2 44yr old Asian Goldman Sachs Executive Slim. Asymptomatic. Non-diabetic. Strong FHx of premature IHD Total cholesterol 7.8 LDL 5.46 HDL 1.23 Non-smoker BP 100/60
JBS3
Case study 2 Rx: Atorvastatin 10mg od
CT coronary angiography
Case study 3 50yr old man. Management Consultant. Asymptomatic CV RF: Strong FHx of IHD (Father/Uncle CABG, Mother PCI), HTn on Lisinopril Total Cholesterol: 5.5 HDL: 1.3 LDL: 3.9
Case study 3
CT Coronary Angiogram Ca++ score 48 (50-75 th centile) 50-70% stenosis in proximal LAD Stress Echocardiogram Reversible ischaemia in LAD territory
Physiologically-guided PCI-LAD
Case study 4 56yr old male. Asymptomatic. Strong FHx of IHD Father MI 61yrs Paternal GF MI 60yrs Uncle fatal MI 60yrs Total cholesterol now controlled with statin TC 4.1, LDL 2.0
Screening history 2014 Exercise ECG ST depression at peak workload. No symptoms. 2014 CTCA Ca++ score 276. Prox LAD stenosis 2014 Invasive cor angio Moderate LMS/LAD disease 2014 Stress echo negative at good workload
Screening history March 2016 repeat stress echo ischaemia at high workload (12 55 ) referred to me. Invasive coronary angiogram with a view to pressure wire assessment
Angiogram 70% 80% 70% Distal LMS/Ostial LAD Underwent CABG x 3
Case study 5 The brother of Case study 4! Asymptomatic Frightened by the story of his brother asked local Cardiologist to screen him for CAD Stress echo negative at high workload. Told not to worry and take a statin (TC 4.0, LDL 2.3, HDL 1.1 on rosuvastatin 5mg) Came to me for second opinion
Case study 5 - screening Cardiac CT Ca++ score 932 dense calcification in LMS, prox and mid-lad. 80th centile. No angiogram performed. Invasive coronary angiogram at patient s (and brother s) insistence!
Coronary angiogram 95% Mid-LAD stenosis PCI LAD with drug-eluting stent
What do we do with asymptomatic coronary disease?
The FAME 2 Trial
FAME 2 De Bruyne et al, NEJM 2014;371:1208
Conclusions Cardiovascular risk predictors are useful tools but only form a framework for management Risk scores should be performed in the context of individual patients CV risk factor management can be enhanced by an individual approach and further tests (CT, PLAC) The evidence base for management of completely asymptomatic CAD is lacking
Thank you! How to refer? Call 0800 783 9229